Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.
2 reports, 2 independent
Updated Sep 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sarepta Therapeutics, which develops precision genetic medicines for DMD, trades on the Nasdaq and is headquartered in Cambridge.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
-
DMD
Nothing else this week.
Related events
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Drugs Made In America Acquisition II Corp. is listed on the Nasdaq exchange.
- Generate Biomedicines Inc listed its shares on the Nasdaq stock exchange on August 25, 2026.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- HCW Biologics announced it is listed on the Nasdaq stock exchange.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- dailypolitical.comAnalysts’ Weekly Ratings Changes for Sarepta Therapeutics (SRPT)